Author Question: Which of the following pulmonary disorders is most likely to result in hepatomegaly? a. Pulmonary ... (Read 25 times)

michelleunicorn

  • Hero Member
  • *****
  • Posts: 565
Which of the following pulmonary disorders is most likely to result in hepatomegaly?
 
  a. Pulmonary atelectasis
  b. Acute viral infections
  c. Cor pulmonale
  d. Acute asthma

Question 2

In which of the following conditions might the intensity of the heart sounds be reduced? 1. Heart failure 2. Severe cachexia 3. Pneumothorax 4. Pleural effusion
 
  a. 1, 3, and 4 only
  b. 2 and 4 only
  c. 2, 3, and 4 only
  d. 1, 2, and 3 only



Perkypinki

  • Sr. Member
  • ****
  • Posts: 339
Answer to Question 1

ANS: C
An enlarged liver is called hepatomegaly and may be caused by right-sided heart failure from chronic hypoxemia (cor pulmonale), although many other causes exist.

Answer to Question 2

ANS: A
Pulmonary hyperinflation, pleural effusion, pneumothorax, and obesity make identification of both S1 and S2 difficult. The intensity of S1 and S2 also decreases when the force of ventricular contraction is poor, as in heart failure, or when valvular abnormalities exist.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

The shortest mature adult human of whom there is independent evidence was Gul Mohammed in India. In 1990, he was measured in New Delhi and stood 22.5 inches tall.

Did you know?

The most common treatment options for addiction include psychotherapy, support groups, and individual counseling.

Did you know?

According to the FDA, adverse drug events harmed or killed approximately 1,200,000 people in the United States in the year 2015.

Did you know?

The eye muscles are the most active muscles in the whole body. The external muscles that move the eyes are the strongest muscles in the human body for the job they have to do. They are 100 times more powerful than they need to be.

Did you know?

For high blood pressure (hypertension), a new class of drug, called a vasopeptidase blocker (inhibitor), has been developed. It decreases blood pressure by simultaneously dilating the peripheral arteries and increasing the body's loss of salt.

For a complete list of videos, visit our video library